Dr. Yang Xiang is an expert in the field of gene and cell therapy, with a Ph.D. from the Chinese Academy of Sciences and postdoctoral training at Harvard Medical School. He has held several positions in the biotech industry, including as a CTO of ABclonal, where he managed customer service across various fields for six years. During the COVID years, he led the development of an mRNA vaccine program at RVAC Medicines as a director.
In 2023, Dr. Xiang joined GenScript as a Senior Field Application Scientist, focusing on gene and cell therapy. He is the first author of a Nature publication and holds U.S. patent on COVID. Dr. Xiang’s diverse background positions him well to continue advancing the field.